Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash & Current Investments (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Cash & Current Investments for 16 consecutive years, with $293.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 17.44% year-over-year to $293.5 million, compared with a TTM value of $293.5 million through Dec 2025, up 17.44%, and an annual FY2025 reading of $293.5 million, up 17.44% over the prior year.
  • Cash & Current Investments was $293.5 million for Q4 2025 at Amicus Therapeutics, up from $263.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $557.0 million in Q3 2021 and bottomed at $231.0 million in Q2 2025.
  • Average Cash & Current Investments over 5 years is $321.2 million, with a median of $283.2 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments increased 23.73% in 2021, then crashed 39.15% in 2022.
  • Year by year, Cash & Current Investments stood at $482.5 million in 2021, then plummeted by 39.15% to $293.6 million in 2022, then fell by 2.52% to $286.2 million in 2023, then decreased by 12.67% to $249.9 million in 2024, then grew by 17.44% to $293.5 million in 2025.
  • Business Quant data shows Cash & Current Investments for FOLD at $293.5 million in Q4 2025, $263.9 million in Q3 2025, and $231.0 million in Q2 2025.